Kazuo Honda

Advanced Science & Technology Enterprise Corp. (ASTEC) is an independent Japanese venture capital firm which was established in 2001 as a 'Kabushiki Kaisha' by Takuro Wakabayashi and a group of professors at the University of Tokyo. The idea was to create a very early-stage venture capital firm to provide support to Japanese technology start-ups with innovative products and services. Based in Tokyo, the firm manages the ASTEC Technology Incubation Fund, backed primarily by institutional investors. They also provide services to help Japanese universities manage collaborative research and consortiums and collaborate with Technology Licensing Organizations to help with commercialization efforts.

Part of Thermo Fisher Scientific, Inc., PPD-SNBL KK is a Japanese company that provides clinical research services. The company is based in Tokyo, Japan.

SNBL USA Ltd. provides general toxicology, acute radiation syndrome, apheresis, CNS drug delivery, immunohistochemistry, tissue cross reactivity and biological services. The company is headquartered in Everrett, WA.

Medipolis Medical Research Institute offers proton beam cancer treatment. The company was founded on March 2006 and is headquartered in Ibusuki, Japan.

Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California.

Part of Mitsubishi Corp., Mitsubishi Corporation LT USA is a company that engages in the distribution of electronics, fuels, metals, and chemicals. The company is based in Schaumburg, IL.

Part of Wave Life Sciences Ltd., Wave Life Sciences USA, Inc. is a company that provides nucleic acid therapeutics. The company is based in Cambridge, MA. The company was founded in 2012 by Gregory L. Verdine, Takeshi Wada. The CEO is Paul B. Bolno.

Advanced Photonics, Inc. is a holding company that designs, develops, and manufactures optical circuit boards. Its products encompass photoelectric conversion modules and optical printed circuit boards. The company was founded by Makotoon Shigematsu on March 15, 2006 and is headquartered in Tokyo, Japan.

Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA.

Dept Corp. engages in the development of electronic devices. It produces self-assembled microscopial structures and thin-film coatings used by liquid-crystal display manufacturers. The company was founded by Takashi Ueno on August 16, 2002 and is headquartered in Tokyo, Japan.

BioMedCore, Inc. provides biotechnology development services. It specializes in the research, development, production, and marketing of liposomal technologies. It also develops treatments for cancer, posterior segment inflammatory diseases, and myocardial reperfusion injury. The company was founded by Yuichiro Satoh and Norio Naruse in December 2005 and is headquartered in Yokohama, Japan.

Jitsubo Co., Ltd. researches, develops, and produces peptides. It operates as a peptide development company that provides solutions to patients using their proprietary technologies for manufacturing and engineering peptides. The firm specializes in peptide synthesis, which enables users to modify amino acid sequence for the creation of physical, chemical, and pharmacological properties. It also engages in development of peptide pharmaceuticals, licensing regarding active ingredient manufacturing technology for peptides, and peptide drug discovery research. The company was founded by Yusuke Kohno and Kazuhiro Chiba in 2000 and is headquartered in Tokyo, Japan.

REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA.